Abrocitinib

Abrocitinib is an oral Janus kinase (JAK) inhibitor used primarily for the treatment of moderate to severe atopic dermatitis (eczema) in adults and adolescents.

Indications

Treatment of moderate to severe atopic dermatitis in adults and adolescents who are candidates for systemic therapy.

Dosage

-The recommended starting dose is 100 mg once daily. -In some cases, a higher dose of 200 mg once daily may be prescribed. -Dose adjustments may be necessary based on individual patient response and tolerability.

Contra-Indications

-Hypersensitivity to Abrocitinib or any of its components. -Severe hepatic impairment. -Active serious infections.

Special Precautions

-Monitor for signs of infection. -Use caution in patients with a history of chronic or recurrent infection. -Regularly monitor blood counts, liver enzymes, and lipid parameters. -Avoid live vaccines during treatment. -Consider the risks and benefits in patients with a history of thrombosis.

Side Effects

-Nausea -Headache -Acne -Herpes simplex infections -Increased blood creatine phosphokinase -Thrombocytopenia

Drug Interactions

-Strong CYP3A4 inhibitors (e.g., ketoconazole) may increase Abrocitinib levels. -Strong CYP3A4 inducers (e.g., rifampin) may decrease Abrocitinib levels. -Avoid concomitant use with other JAK inhibitors, biologic immunomodulators, or potent immunosuppressants.